Recent Comments

Comment RSS

Parkinson's Disease News and Research RSS Feed - Parkinson's Disease News and Research Twitter

Parkinson's disease is a brain disorder. It occurs when certain nerve cells (neurons) in a part of the brain called the substantia nigra die or become impaired. When approximately 80 percent of neurons are damaged, the symptoms of Parkinson's disease appear. Parkinson's disease affects 1 in 100 people over the age of 60, with the average age of onset being 60 years. The risk of developing Parkinson's disease increases with age. In the United States, it is estimated that 60,000 new cases of Parkinson's disease are diagnosed each year, with 1.5 million Americans currently living with the disease.

Review of R&D and novel therapeutic challenges in neurological disorders

20. November 2009 04:39
Research and Markets (http://www.researchandmarkets.com/research/fae4d4/neurological_disea) has announced the addition of Decision Resources, Inc.'s new report "Neurological Disease: Early-Stage R&D and Dealmaking" to their offering. [More]

Health technology assessment to influence coverage of neurology drugs in most markets

20. November 2009 03:16
Research and Markets (http://www.researchandmarkets.com/research/60b63b/the_pricing_and_re) has announced the addition of Decision Resources, Inc.'s new report "The Pricing and Reimbursement Environment for Neurology Drugs" to their offering. [More]

Comprehensive report on neurodegenerative disorders market

19. November 2009 23:57
Research and Markets (http://www.researchandmarkets.com/research/5f3158/alzheimers_and_pa) has announced the addition of the "Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities" report to their offering. [More]

Posted in: Medical Condition News

Tags: , ,

MONITORING FORCE files for Flibanserin orphan drug status designation with the EMEA

19. November 2009 11:24
MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: ,

AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

19. November 2009 05:33
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , ,

Data from Phase 1 safety study of SB-728-T announced

19. November 2009 03:20
Sangamo BioSciences, Inc. announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet. [More]

New mathematical model may hasten drug development for Parkinson's Disease

19. November 2009 01:52
Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease. [More]

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

19. November 2009 01:42
Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries. [More]

Women with multiple sclerosis are less likely to have pregnancy complicaitons

19. November 2009 00:55
There is good news for women with multiple sclerosis (MS) who are pregnant or thinking about becoming pregnant. A new study shows that pregnant women with multiple sclerosis are only slightly more likely to have cesarean deliveries and babies with a poor prenatal growth rate than women who do not have MS. [More]

Gene that tells embryonic stem cells when to stop producing neurons identified

18. November 2009 07:00
Researchers from North Carolina State University have identified a gene that tells embryonic stem cells in the brain when to stop producing nerve cells called neurons. The research is a significant advance in understanding the development of the nervous system, which is essential to addressing conditions such as Parkinson's disease, Alzheimer's disease and other neurological disorders. [More]

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

18. November 2009 04:43
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. [More]

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

18. November 2009 04:03
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009. [More]

Recent developments at Burnham Institute for Medical Research

17. November 2009 04:58
New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases). [More]

Assessing the neurology market and its major players

17. November 2009 04:13
Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering. [More]

Self-care tips for hemorrhoids from Mayo Clinic

16. November 2009 07:28
By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.